Our results demonstrate that anti-PD1 therapy when combined with pharmacologic inhibitor cause suppression of tumor growth in syngeneic mouse model compared to single agent therapy as well as improved survival rate.
Our overall goal is to create a more effective CAR-T for the control of HIV. A similar strategy could be adopted to treat other chronic viral infections.